RedHill Biopharma Ltd.
RDHL
$1.02
-$0.01-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -33.84% | -33.84% | 80.88% |
| Total Depreciation and Amortization | -- | -- | -59.81% | -59.81% | -50.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 92.09% | 92.09% | -95.35% |
| Change in Net Operating Assets | -- | -- | -132.84% | -132.84% | 102.19% |
| Cash from Operations | -- | -- | 18.92% | 18.92% | -111.61% |
| Capital Expenditure | -- | -- | -300.00% | -300.00% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -300.00% | -300.00% | -172.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 54.35% | 54.35% | 62.12% |
| Issuance of Common Stock | -- | -- | -58.27% | -58.27% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 97.13% |
| Cash from Financing | -- | -- | -58.75% | -58.75% | -143.27% |
| Foreign Exchange rate Adjustments | -- | -- | 250.00% | 250.00% | 178.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -202.52% | -202.52% | -113.09% |